SMT201600069B - Composizioni comprendenti 15-hepe e metodi d’uso delle stesse - Google Patents

Composizioni comprendenti 15-hepe e metodi d’uso delle stesse

Info

Publication number
SMT201600069B
SMT201600069B SM201600069T SM201600069T SMT201600069B SM T201600069 B SMT201600069 B SM T201600069B SM 201600069 T SM201600069 T SM 201600069T SM 201600069 T SM201600069 T SM 201600069T SM T201600069 B SMT201600069 B SM T201600069B
Authority
SM
San Marino
Prior art keywords
hepe
methods
same
compositions including
compositions
Prior art date
Application number
SM201600069T
Other languages
English (en)
Inventor
Jonathan Rowe
Kevin Duffy
John Climax
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of SMT201600069B publication Critical patent/SMT201600069B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
SM201600069T 2013-01-30 2016-03-08 Composizioni comprendenti 15-hepe e metodi d’uso delle stesse SMT201600069B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same

Publications (1)

Publication Number Publication Date
SMT201600069B true SMT201600069B (it) 2016-04-29

Family

ID=47891001

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600069T SMT201600069B (it) 2013-01-30 2016-03-08 Composizioni comprendenti 15-hepe e metodi d’uso delle stesse

Country Status (27)

Country Link
US (6) US20150224076A1 (it)
EP (2) EP2762143B1 (it)
JP (2) JP6363104B2 (it)
KR (6) KR20230047201A (it)
CN (2) CN111214464A (it)
AU (2) AU2014211628B2 (it)
BR (1) BR112015018270A2 (it)
CA (1) CA2897343C (it)
CY (1) CY1117209T1 (it)
DK (1) DK2762143T3 (it)
ES (2) ES2759448T3 (it)
GB (1) GB201301626D0 (it)
HR (1) HRP20160203T1 (it)
HU (1) HUE026901T2 (it)
IL (3) IL239893A (it)
MX (2) MX364646B (it)
NZ (1) NZ709803A (it)
PH (1) PH12015501582B1 (it)
PL (1) PL2762143T3 (it)
PT (1) PT2762143E (it)
RS (1) RS54584B1 (it)
RU (2) RU2018136872A (it)
SG (2) SG10201806854XA (it)
SI (1) SI2762143T1 (it)
SM (1) SMT201600069B (it)
WO (1) WO2014118097A1 (it)
ZA (2) ZA201505018B (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018502163A (ja) * 2015-01-16 2018-01-25 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びそれを使用する方法
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
WO2016181221A1 (en) * 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
CA3008774C (en) * 2015-12-18 2021-10-12 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
CN1202068C (zh) 2000-02-16 2005-05-18 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
CZ299784B6 (cs) 2001-05-30 2008-11-26 Laxdale Limited Lécivo obsahující EPA a ubichinon pro lécení non-Hodgkinova lymfomu, psychiatrických a neurologických chorob
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
WO2006007510A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
WO2007081773A2 (en) * 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
CA2662987A1 (en) 2006-08-08 2008-02-21 Tethys Bioscience, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
WO2008126363A1 (ja) * 2007-03-30 2008-10-23 Kowa Company, Ltd. 脂肪肝又は非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP2415748A4 (en) * 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US9238634B2 (en) * 2010-08-19 2016-01-19 The University Of Tokyo Anti-inflammatory metabolite derived from omega-3-type fatty acid
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2014530841A (ja) 2011-10-19 2014-11-20 ディグニティサイエンシスリミテッド Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP4205546A1 (en) * 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018520197A (ja) * 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
CA3008774C (en) 2015-12-18 2021-10-12 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Also Published As

Publication number Publication date
EP2762143A1 (en) 2014-08-06
KR20150112995A (ko) 2015-10-07
CN111214464A (zh) 2020-06-02
JP2016511753A (ja) 2016-04-21
HRP20160203T1 (hr) 2016-03-25
EP2762143B1 (en) 2015-12-02
RS54584B1 (sr) 2016-08-31
IL239893A0 (en) 2015-08-31
AU2014211628A1 (en) 2015-07-30
ZA201505018B (en) 2017-01-25
HUE026901T2 (en) 2016-07-28
US20210244697A1 (en) 2021-08-12
CA2897343A1 (en) 2014-08-07
MX2019005082A (es) 2019-08-12
KR102514913B1 (ko) 2023-03-27
ES2759448T3 (es) 2020-05-11
WO2014118097A1 (en) 2014-08-07
NZ709803A (en) 2020-05-29
SI2762143T1 (sl) 2016-04-29
SG10201806854XA (en) 2018-09-27
IL251639A0 (en) 2017-06-29
KR20240011872A (ko) 2024-01-26
KR20230047201A (ko) 2023-04-06
AU2014211628B2 (en) 2018-04-19
BR112015018270A2 (pt) 2017-07-18
US20150224076A1 (en) 2015-08-13
SG11201505457PA (en) 2015-08-28
US20220347147A1 (en) 2022-11-03
KR102274963B1 (ko) 2021-07-08
RU2015136849A (ru) 2017-03-06
KR102434817B1 (ko) 2022-08-19
EP3058943B1 (en) 2019-09-25
US20200069626A1 (en) 2020-03-05
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
MX364646B (es) 2019-05-03
KR20210088733A (ko) 2021-07-14
JP6363104B2 (ja) 2018-07-25
EP3058943A1 (en) 2016-08-24
JP2018172409A (ja) 2018-11-08
RU2671208C2 (ru) 2018-10-30
PL2762143T3 (pl) 2016-06-30
CN105120872B (zh) 2020-01-10
ES2564025T3 (es) 2016-03-17
PH12015501582A1 (en) 2015-10-05
KR20220119524A (ko) 2022-08-29
US10813903B2 (en) 2020-10-27
GB201301626D0 (en) 2013-03-13
US20210228524A1 (en) 2021-07-29
IL239893A (en) 2017-04-30
CN105120872A (zh) 2015-12-02
US20250186384A1 (en) 2025-06-12
KR20250105691A (ko) 2025-07-08
HK1200351A1 (en) 2015-08-07
MX2015009803A (es) 2015-10-29
IL265876A (en) 2019-06-30
AU2018206685A1 (en) 2018-08-02
PT2762143E (pt) 2016-03-28
CY1117209T1 (el) 2017-04-05
DK2762143T3 (en) 2016-03-07
CA2897343C (en) 2021-03-16
ZA201605125B (en) 2018-06-27

Similar Documents

Publication Publication Date Title
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
IL241112B (en) Methods and compositions for modification of hla
PT3259253T (pt) Sulfonilureias e compostos relacionados e uso dos mesmos
CL2016002416A1 (es) Composiciones estables de yodo no en complejo y métodos de uso
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
AR094502A1 (es) Pirazoles sustituidos en posicion 3 y usos de los mismos
IL241184A0 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
BR112015028459A2 (pt) composições e comestíveis
BR112015030525A2 (pt) nanopartícula, kit, método de preparação de uma nanopartícula, e uso da nanopartícula
CL2015003441A1 (es) Composiciones de arní de serpina1 y sus métodos de uso
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
PL3007687T3 (pl) Kombinacja pentacyklicznych triterpenów i hydroksytyrozolu oraz jego pochodnych
BR112016006614A2 (pt) composições de trichoderma e métodos de uso
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
HUE053033T2 (hu) Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
HUE043417T2 (hu) Krémesítõ kompozíciók és alkalmazásuk
BR112015016548A2 (pt) polimixinas , composições , métodos de preparação e métodos de uso
DK2956471T3 (da) Il-1beta-hæmmersammensætning og anvendelse deraf
BR112016004943A2 (pt) aparelho médico e uso
IL264445A (en) Compounds and compositions and uses thereof
BR112014026880A2 (pt) composição de sensibilização e método de uso
SMT201700004B (it) Uso di estratti di salvia haenkei in composizioni per antisenescenza
FR3007291B1 (fr) Composition cicatrisante et utlisation
BR112015008353A2 (pt) uso cosmético e métodos cosméticos